Coating-Dependent Biodistribution of Magnetite Nanoparticles

An in vivo comparison of magnetite nanoparticles with multiple surface coatings quantified circulation kinetics and organ biodistribution using magnetic particle quantification (MPQ), with readouts spanning major organs as well as tumor and brain. Across formulations, the authors describe coating-dependent differences in how long particles remained detectable in blood and where signal accumulated after administration, alongside a histology-based assessment of tumor penetration depth. The dataset also contrasts passive delivery with externally guided delivery using a local magnetic field over the tumor region. The paper reports circulation, biodistribution, and tumor-facing endpoints stratified by nanoparticle coating within a single experimental design.

The authors tested 17 coating variants selected from a broader set, spanning polymer-, lectin-, and small-molecule–based surface chemistries, and using MPQ as the quantitative readout for both circulation and ex vivo tissue measurements. For tumor-facing distribution, they also describe histological processing of tumor sections and image-based measurement of nanoparticle penetration depth. During physicochemical quality assessment, they describe uncertainty about successful formation of the polyethylene glycol layer and note that this formulation was excluded from subsequent in vivo experiments because available data were judged insufficient to confirm coating formation.

For circulation kinetics, the authors report statistically significant differences in blood circulation half-life for higher-molecular-weight carboxymethyldextran (CMD) coatings—specifically CMD 40, 70, and 150 kDa—when compared with uncoated magnetite. When distribution was assessed across harvested tissues, the authors report that the dominant signal localized to mononuclear phagocyte system organs, with approximately 80–90% of injected dose in liver and 5–15% in spleen across most formulations under both passive and magnetic-field conditions (noting that passive-targeting biodistribution was measured at 24 h post-injection, whereas magnetic-targeting biodistribution was measured after 3 h of circulation with a magnet applied for 3 h). They also present supplemental organ panels in which several smaller tissues (including kidney, muscle, bone, brain, and heart) are shown with uptake below 1% of injected dose. Overall, these results are presented as showing that coating choice can shift circulation metrics while organ-level recovery remains heavily weighted toward mononuclear phagocyte system organs (e.g., liver and spleen).

Tumor-facing analyses separate passive accumulation from externally guided delivery and relate both to coating identity. Under passive targeting, the authors report that (CMD 150 kDa)@NPs had higher tumor accumulation than uncoated particles with statistical significance, and they describe a strong positive Pearson correlation between CMD molecular weight and passive tumor delivery efficiency (R = 0.972). Under magnetic targeting, they report that average tumor accumulation increased for many formulations, with statistically significant increases highlighted for CMD 4 kDa, PVP, PSSS 70 kDa, and chitosan in their comparisons. In histology-based penetration assessments, the authors further report coating-dependent shifts with magnetic application, including deeper penetration for CMD 4 kDa, CMD 70 kDa, and PAA, and reduced penetration for PVP, SBA, and PEI 50 mg. Overall, the reported tumor accumulation and penetration responses differ by coating and by whether delivery was passive or magnetically guided.

Key Takeaways:

• The authors report that higher-molecular-weight CMD coatings (CMD 40–150 kDa) were associated with longer blood circulation half-life than uncoated magnetite in their MPQ-derived analyses.
• Across formulations, most recovered signal was reported in liver and spleen, with organ-level ranges dominated by approximately 80–90% and 5–15% of injected dose, respectively.
• Compared with passive delivery, magnetic targeting was reported to increase average tumor accumulation for many coatings and to change penetration depth in a coating-dependent manner.